RESUMO
BACKGROUND: Severe perinatal depression is a significant cause of mortality and morbidity in neonates. Vitamin D levels were observed to be low in mothers and their neonates with hypoxic ischemic encephalopathy in some studies, owing to its neuroprotective properties. OBJECTIVE: Primary objective was to compare vitamin D deficiency state in full term neonates with severe perinatal depression and healthy term controls. Secondary objectives were to determine sensitivity and specificity of serum 25(OH)D<12âng/mL in predicting mortality, development of hypoxic ischemic encephalopathy, abnormal neurological examination at discharge, and developmental outcome at 12 weeks of age. MATERIAL AND METHODS: Serum 25(OH)D levels in full term neonates with severe perinatal depression and healthy controls were compared. RESULTS: Serum 25(OH)D levels in severe perinatal depression and controls (nâ=â55 each group) were significantly different (7.50 ± 3.53âng/mL vs 20.23 ± 12.70âng/mL). At cut-off ofâ<â12âng/mL, serum 25(OH)D could predict mortality with 100% sensitivity and 17% specificity and poor developmental outcomes with sensitivity of 100% and specificity of 50%. CONCLUSION: Vitamin D deficiency status at birth can serve as an effective screening tool and poor prognostic markers in term neonates with severe perinatal depression.
Assuntos
Asfixia Neonatal , Hipóxia-Isquemia Encefálica , Deficiência de Vitamina D , Recém-Nascido , Gravidez , Feminino , Humanos , Vitamina D , Depressão , Hipóxia-Isquemia Encefálica/complicações , Asfixia Neonatal/complicaçõesRESUMO
With improved and prolonged survival of very and extremely low birth weight infants, invasive fungal infection has emerged as an important concern in the neonatal intensive care units. Candidiasis is the third leading cause of late onset sepsis in these neonates and is associated with 20-30% mortality. Extreme prematurity, central venous catheters, prolonged antibiotic exposure, parenteral nutrition are important risk factors. Various forms of cutaneous manifestations of candidiasis have been described ranging from local diaper dermatitis and oral thrush to widespread erosive and ulcerative lesions with extensive crusting in invasive fungal dermatitis. We report a series of four cases with cutaneous hyperpigmentation as manifestation of systemic candidiasis.
Assuntos
Candidemia/fisiopatologia , Hiperpigmentação/patologia , Sepse Neonatal/fisiopatologia , Anfotericina B/uso terapêutico , Antibacterianos/uso terapêutico , Antifúngicos/uso terapêutico , Candidemia/complicações , Candidemia/tratamento farmacológico , Candidíase Invasiva/complicações , Candidíase Invasiva/tratamento farmacológico , Candidíase Invasiva/fisiopatologia , Feminino , Humanos , Hiperpigmentação/etiologia , Recém-Nascido , Recém-Nascido Prematuro , Unidades de Terapia Intensiva Neonatal , Masculino , Sepse Neonatal/complicaçõesRESUMO
BACKGROUND: Statins reduce coronary events in patients with coronary artery disease. MATERIAL/METHODS: Chart reviews were performed in 305 patients (217 men and 88 women, mean age 74 years) not treated with statins during the first year of being seen in an outpatient cardiology practice but subsequently treated with statins. Based on the starting date of statins use, the long-term outcomes of myocardial infarction (MI), percutaneous coronary intervention (PCI), and coronary artery bypass graft surgery (CABGS) before and after statin use were compared. RESULTS: Mean follow-up was 65 months before statins use and 66 months after statins use. MI occurred in 31 of 305 patients (10%) before statins, and in 13 of 305 patients (4%) after statins (p < 0.01). PCI had been performed in 66 of 305 patients (22%) before statins and was performed in 41 of 305 patients (13%) after statins (p < 0.01). CABGS had been performed in 56 of 305 patients (18%) before statins and was performed in 20 of 305 patients (7%) after statins (p < 0.001). Stepwise logistic regression showed statins use was an independent risk factor for MI (odds ratio = 0.0207, 95% CI, 0.0082-0.0522, p < 0.0001), PCI (odds ratio = 0.0109, 95% CI, 0.0038-0.0315, p < 0.0001), and CABGS (odds ratio = 0.0177, 95% CI = 0.0072-0.0431, p<0.0001.) CONCLUSIONS: Statins use in an outpatient cardiology practice reduces the incidence of MI, PCI, and CABGS.
Assuntos
Cardiologia , Doenças Cardiovasculares/tratamento farmacológico , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Pacientes Ambulatoriais , Padrões de Prática Médica , Idoso , Feminino , Humanos , Incidência , Masculino , Infarto do Miocárdio/tratamento farmacológico , Infarto do Miocárdio/epidemiologia , Revascularização Miocárdica , Fatores de Tempo , Resultado do TratamentoRESUMO
Folic acid supplementation is important in the prevention of Neural Tube Defects (NTD). The study was conducted to assess the awareness amongst physicians regarding the role of Folic Acid (FA) in the prevention of NTD. Physicians were interviewed regarding the awareness of FA dose, timing of supplementation and knowledge about its role in prevention of neural tube defects using a semistructured questionnaire. Among 202 physicians interviewed (48 pediatricians, 54 obstetricians, 100 recently qualified medical graduates) overall awareness about FA was present in 92.07%, similar in three groups (P > 0.05). Only 47.52% were aware of preconception administration, 61.38% about dose of supplementation and 11.88% about recurrence rate of NTD. Only 15 (7.4%) knew all these. Regarding the etiology of NTDs only 26.7% said both FA and genetic factors are involved. Though majority were aware that folic acid has a role in prevention of NTDs, their knowledge about timing and dose of supplementation was lacking. Hence attempts should be made to increase the awareness regarding prevention of NTD's by FA supplementation at a proper time.
Assuntos
Ácido Fólico/administração & dosagem , Conhecimentos, Atitudes e Prática em Saúde , Defeitos do Tubo Neural/prevenção & controle , Médicos/estatística & dados numéricos , Suplementos Nutricionais/normas , Feminino , Alimentos Fortificados/normas , Humanos , Índia , Obstetrícia , Pediatria , Cuidado Pré-Concepcional/normas , Cuidado Pré-Concepcional/estatística & dados numéricos , Gravidez , Inquéritos e QuestionáriosRESUMO
OBJECTIVES: To compare the lipid profiles of exclusively breastfed and mixed-fed term healthy infants in the first 6 months of life. DESIGN: Prospective comparative study. SETTING: Study was carried out in a tertiary care hospital. SUBJECTS: Four hundred consecutive term healthy infants, 200 on exclusive breastfeeding (group 1) and 200 receiving mixed feeding (group 2) were recruited at 14 weeks of age. At 6 months, 149 and 150 mother-infant pairs were followed up in groups 1 and 2, respectively. METHODS: Anthropometric measures of the mother and baby were recorded. Serum lipid levels of the mother and babies were determined at 14 weeks. Babies were followed up till 6 months and their lipid levels were determined again at 6 months. Statistical analysis was carried out using SPSS. RESULTS: Two groups were comparable in birth weight and maternal characteristics (P>0.05). Weight and head circumference were significantly more in the breastfed group at 14 weeks as well as at 6 months (P<0.001). Mean total cholesterol (TC) was 205.27+/-47.31 and 176.55+/-32.01 mg/dl in groups 1 and 2, respectively at 14 weeks (CI=20.77-36.66, P<0.001). At 6 months TC was 192.79+/-40.52 and 161.05+/-22.53 mg/dl in the two groups (CI=24.26-39.22, P<0.001). Change in total cholesterol from 14 weeks to 6 months was also significant in both groups (P<0.001). Low-density lipoprotein cholesterol (LDL-C) and triglycerides were significantly higher in the breastfed groups at 14 weeks and 6 months. The high-density lipoprotein cholesterol (HDL-C)/LDL-C significantly improved at 6 months in exclusively breastfed group (P=0.045). A positive correlation was found only at 14 weeks between mother's TC and baby's TC (r=0.332), mother's LDL-C with baby's LDL-C (r=0.223) in mixed fed group. CONCLUSION: Breastfed babies have significantly higher TC and LDL-C compared to mixed fed babies in the first 6 months of life with improving HDL-C/LDL-C ratio at 6 months. SPONSORSHIP: None.